Save time and jump to the most important pieces.
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival Pre-operative treatments from CEL-SCI and Merck have the potential to offer clinical benefit for locally advanced resectable head and neck cancer patients across the PD-L1 expression spectrum CEL-SCI Corporation (NYSE:CV
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $2.50 per share. Total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, were $5,000,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments at the public offering price, less the underwriting discount. The Company intends to use the net proceeds from this offering to fund the continued development of Multik
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $2.50 per share. Total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, are expected to be $5,000,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 190,000 shares to cover over-allotments at the public offering price, less the underwriting discount. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closin
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
8-K - CEL SCI CORP (0000725363) (Filer)
424B5 - CEL SCI CORP (0000725363) (Filer)
424B5 - CEL SCI CORP (0000725363) (Filer)
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)